Previous 10 | Next 10 |
Lexaria Bioscience is a global innovator in drug delivery platforms whose lead technology, DehydraTECH, has been shown to increase the bioavailability of APIs The company recently announced that Catherine Turkel, PharmD, Ph.D., has joined its board of directors Dr. Turkel, who brings ...
The shares of clinical-stage biotech Eledon Pharmaceuticals, Inc. ( NASDAQ: ELDN ) gained 10% in post-market trading Friday after the company announced that the FDA cleared its Investigational New Drug (IND) application for kidney disease therapy tegoprubart. Phase 2a ...
IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to evaluate tegoprubart for the trea...
Lexaria Bioscience (NASDAQ: LEXX) , a global innovator in drug-delivery platforms, has announced an addition to its board of directors; the company named industry veteran Catherine Turkel, PharmD, PhD, as the newest member of its board. Turkel brings more than two decades of experience as a...
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming investor conferences: A fireside chat at the virtual Gilmartin Group Emerging Growth Compan...
Eledon Pharmaceuticals, Inc. (ELDN) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Paul Little - CFO David-Alexandre Gros - CEO Steve Perrin - President and Chief Scientific Officer Jeff Bornstein - Chief Medical Officer ...
The following slide deck was published by Eledon Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Eledon Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation
Eledon Pharmaceuticals press release ( NASDAQ: ELDN ): Q2 GAAP EPS of -$0.65 beats by $0.05 . The company had approximately $70.5 million in cash and cash equivalents as of June 30, 2022, compared to $84.8 million in cash and cash equivalents as of December 31, 2021. ...
Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients First patient dosed in Phase 1b trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients in Cana...
The following slide deck was published by Eledon Pharmaceuticals, Inc. in conjunction with this event. For further details see: Eledon Pharmaceuticals (ELDN) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Eledon Pharmaceuticals Inc Com Company Name:
ELDN Stock Symbol:
NASDAQ Market:
Eledon Pharmaceuticals Inc Com Website:
IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company’s management team will be hosting one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism, on July 9, ...
Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 post-transplant of 70.5 mL/min/1.73m² Mean eGFR measured above 60 mL/min/1.73m...